Literature DB >> 26454786

Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups.

Amedeo Lonardo1, Stefano Bellentani2, Curtis K Argo3, Stefano Ballestri4, Christopher D Byrne5, Stephen H Caldwell3, Helena Cortez-Pinto6, Antonio Grieco7, Mariana V Machado6, Luca Miele7, Giovanni Targher8.   

Abstract

An improved understanding of non-alcoholic fatty liver disease epidemiology would lead to identification of individuals at high risk of developing chronic liver disease and extra-hepatic complications, thus contributing to more effective case finding of non-alcoholic fatty liver disease among selected groups. We aimed to illustrate the epidemiology of non-alcoholic fatty liver disease in high-risk groups, which were identified based on existing literature. To this end, PubMed was searched to retrieve original articles published until May 2015 using relevant and pertinent keywords "nonalcoholic fatty liver disease" and "diabetes", "obesity", "hyperlipidaemia", "familial heterozygous hypobetalipoproteinaemia", "hypertension", "metabolic syndrome", "ethnicity", "family history" or "genetic polymorphisms". We found that age, sex and ethnicity are major physiological modifiers of the risk of non-alcoholic fatty liver disease, along with belonging to "non-alcoholic fatty liver disease families" and carrying risk alleles for selected genetic polymorphisms. Metabolic syndrome, diabetes, obesity, mixed hyperlipidaemia and hypocholesterolaemia due to familial hypobetalipoproteinaemia are the major metabolic modifiers of non-alcoholic fatty liver disease risk. Compared with these metabolic conditions, however, arterial hypertension appears to carry a relatively more modest risk of non-alcoholic fatty liver disease. A better understanding of the epidemiology of non-alcoholic fatty liver disease may result in a more liberal policy of case finding among high-risk groups.
Copyright © 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dyslipidaemia; Metabolic syndrome; NAFLD; Obesity; Type 2 diabetes mellitus

Mesh:

Year:  2015        PMID: 26454786     DOI: 10.1016/j.dld.2015.08.004

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  127 in total

1.  Serum 25-hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort.

Authors:  Samar R El Khoudary; Saad Samargandy; Irfan Zeb; Temitope Foster; Ian H de Boer; Dong Li; Matthew J Budoff
Journal:  Nutr Metab Cardiovasc Dis       Date:  2019-09-10       Impact factor: 4.222

2.  Impact of miR-140 Deficiency on Non-Alcoholic Fatty Liver Disease.

Authors:  Benjamin Wolfson; Pang-Kuo Lo; Yuan Yao; Linhao Li; Hongbing Wang; Qun Zhou
Journal:  Mol Nutr Food Res       Date:  2018-06-12       Impact factor: 5.914

3.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?

Authors:  Christopher D Byrne; Giovanni Targher
Journal:  Diabetologia       Date:  2016-04-07       Impact factor: 10.122

Review 4.  Cardiac abnormalities in patients with nonalcoholic fatty liver disease : Insights from auxiliary examinations.

Authors:  Yu Dong; Guangsen Li
Journal:  Herz       Date:  2019-09-19       Impact factor: 1.443

Review 5.  Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.

Authors:  Alessandro Mantovani; Giovanni Targher
Journal:  Ann Transl Med       Date:  2017-07

Review 6.  Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ma Ai Thanda Han; Rola Saouaf; Walid Ayoub; Tsuyoshi Todo; Edward Mena; Mazen Noureddin
Journal:  Expert Rev Clin Pharmacol       Date:  2017-03-09       Impact factor: 5.045

7.  Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes.

Authors:  E Cipponeri; N Vitturi; V Mariano; F Boscari; S Galasso; C Crepaldi; G P Fadini; S Vigili de Kreutzenberg; M C Marescotti; E Iori; F Cavallin; L Sartori; A Baritussio; A Avogaro; D Bruttomesso
Journal:  J Endocrinol Invest       Date:  2019-03-07       Impact factor: 4.256

8.  What Is the Role of the New Index Relative Fat Mass (RFM) in the Assessment of Nonalcoholic Fatty Liver Disease (NAFLD)?

Authors:  Mariana V Machado; Sara Policarpo; J Coutinho; Sofia Carvalhana; Jorge Leitão; Armando Carvalho; Ana P Silva; Francisco Velasco; Isabel Medeiros; Ana Catarina Alves; Mafalda Bourbon; Helena Cortez-Pinto
Journal:  Obes Surg       Date:  2020-02       Impact factor: 4.129

Review 9.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Authors:  Giovanni Targher; Amedeo Lonardo; Christopher D Byrne
Journal:  Nat Rev Endocrinol       Date:  2017-12-29       Impact factor: 43.330

10.  Association between non-alcoholic hepatic steatosis and hyper reactive blood pressure response on the exercise treadmill test.

Authors:  A G Laurinavicius; M S Bittencourt; M J Blaha; F C Nary; N M Kashiwagi; R D Conceiçao; R S Meneghelo; R R Prado; J A M Carvalho; K Nasir; R S Blumenthal; R D Santos
Journal:  QJM       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.